THU0021 Differential effects of tr14 versus diclofenac on cox/lox pathways revealed by rnaseq

@inproceedings{Laurent2018THU0021DE,
  title={THU0021 Differential effects of tr14 versus diclofenac on cox/lox pathways revealed by rnaseq},
  author={Georges St. Laurent and Ian Toma and Bernd Seilheimer and Michael R. Tackett and Jianhua Zhou and Maxim T Ri and Dmitry Shtokalo and Yuri Vyatkin and Terry Jepson and Konstantin Cesnulevicius and Timothy A. McCaffrey},
  year={2018}
}
  • Georges St. Laurent, Ian Toma, +8 authors Timothy A. McCaffrey
  • Published 2018
  • Medicine
  • Background Anti-inflammatory agents are used widely in treating numerous pain and inflammatory conditions. With a focus on the COX/LOX pathways in cutaneous wound repair in mice, the therapeutic activities of Tr14 (Traumeel), a multicomponent/multitarget natural product, and diclofenac (NSAID), a non-selective cyclooxygenase (COX) inhibitor were compared. The COX enzymes convert arachidonic acid into prostaglandins and thromboxanes, while the lipoxygenase (LOX) pathway generates more pro… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv